Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case

The new generation conjugate trastuzumab deruxtecan (Т-DXd) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have previously received a drug regimen containing anti-HER2 targeted agents, as well as for the treatment of adult patien...

Full description

Saved in:
Bibliographic Details
Main Authors: R. A. Murashko, S. V. Sharov, E. P. Chashnikova
Format: Article
Language:Russian
Published: ABV-press 2025-03-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1322
Tags: Add Tag
No Tags, Be the first to tag this record!